Nektar Therapeutics (NKTR) Current Assets (2010 - 2026)

Nektar Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $589.0 million for Q1 2026.

• On a quarterly basis, Current Assets rose 156.2% year-over-year to $589.0 million in Q1 2026; TTM through Mar 2026 was $589.0 million, a 156.2% increase from a year earlier, with the FY2025 full-year figure at $266.3 million, up 1.9% from the prior year.
• Current Assets improved to $589.0 million in Q1 2026 per NKTR's latest filing, from $266.3 million in the prior quarter.
• Across five years, Current Assets topped out at $733.5 million in Q1 2022 and bottomed at $186.6 million in Q2 2025.
• The 5-year median for Current Assets is $330.7 million (2023), against an average of $407.2 million.
• Across the five-year window, Current Assets slumped 39.43% in 2023 and jumped 156.2% in 2026, its largest moves.
• Year by year, Current Assets stood at $546.0 million in 2022, then slumped by 39.43% to $330.7 million in 2023, then declined by 20.99% to $261.3 million in 2024, then rose by 1.9% to $266.3 million in 2025, then soared by 121.22% to $589.0 million in 2026.
• Per Business Quant, the three latest NKTR Current Assets figures stand at $589.0 million (Q1 2026), $266.3 million (Q4 2025), and $281.4 million (Q3 2025).